Alpha Tau Medical Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 16, 2026, transmitting a press release announcing positive interim results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial.
Key Highlights
- All patients alive: According to the filing, all patients treated in the trial are alive, with median survival not yet reached.
- 100% objective response rate: The company disclosed a 100% ORR among the first six evaluable patients.
- Median follow-up of 6.9 months: The filing states a median follow-up of 6.9 months across those six patients.
- 100% feasibility: The press release, as cited in the filing, reported 100% feasibility for the procedure.
- No unanticipated serious adverse events: The company disclosed that no unanticipated serious adverse events were observed in this interim readout.
- Conference call scheduled: A conference call was scheduled for 8:30am ET on November 16, 2026, according to the filing.
Interim Results From Alpha Tau's Recurrent Glioblastoma Study
Alpha Tau Medical Ltd. (NASDAQ:DRTS), a Jerusalem, Israel-based medical technology company, filed a Form 6-K for the month of November 2026, attaching a press release dated November 15, 2026. The press release announced what the company described as new positive interim results from its U.S. clinical trial evaluating Alpha DaRT technology in patients with recurrent glioblastoma, a form of aggressive brain cancer that typically carries a poor prognosis after prior treatment.
Alpha DaRT, which stands for Diffusing Alpha-emitter Radiation Therapy, is the company's proprietary technology platform. According to the filing, the interim data covered the first six evaluable patients enrolled in the U.S. trial. The company reported a 100% objective response rate and 100% feasibility, with all treated patients remaining alive and median overall survival not yet reached at the time of the data cutoff. The median follow-up period across these patients was 6.9 months, as stated in the press release title reproduced in the filing.
The filing also noted that no unanticipated serious adverse events were observed among the patients covered by this interim analysis. The Form 6-K was signed by Uzi Sofer, Chief Executive Officer of Alpha Tau Medical Ltd., on November 16, 2026, under Commission File Number 001-41316. The company files annual reports on Form 20-F and is classified as a foreign private issuer under the Securities Exchange Act of 1934.
What Was Disclosed
The Form 6-K transmitted a single exhibit, the press release dated November 15, 2026, which contained the interim clinical trial data described above. The filing itself does not reproduce the full text of the press release; the substantive clinical details appear in the press release title as quoted within the Form 6-K body.
The filing confirms Alpha Tau Medical as the registrant, identifies Uzi Sofer as the authorized signatory in his capacity as Chief Executive Officer, and establishes the reporting period as the month of November 2026. No financial statements, revenue figures, or guidance were included in this Form 6-K submission.



Please wait processing your request...